IL6 and breast carcinoma: Other investigators discovered associations of high serum IL-6 levels with poor response to therapy, including resistance to chemotherapy and endocrine therapy, providing the rationale for combination treatment of breast cancer therapy with Ruxolitinib [135,136,137].